Recombinant Cell Culture Supplements Market

The Recombinant Cell Culture Supplements Market Size is valued at 346.74 million in 2022 and is predicted to reach 1003.55 million by the year 2031 at a 12.70% CAGR during the forecast period for 2023-2031.

Rising demand for cell culture supplements, increased mergers and acquisitions to diversify the portfolio of recombinant cell culture supplements, and increased funding for biopharmaceutical product research and development in the life sciences sector are some factors boosting market growth. Other factors boosting market growth include rising demand for stem cell and regenerative medicine research, immunotherapy, and the need for animal-free supplements in cell culture applications. Regulatory bodies are also pushing for the use of animal-free media supplements in cell culture processes. The growth is anticipated to be inhibited by the high cost, the technical difficulties related to recombinant cell culture supplements, and the shortage of qualified personnel.

Competitive Landscape:

Some of the recombinant cell culture supplements market players are:

Abcam plc.
Corning Incorporated
Lonza Group AG
Merck KGaA
Sartorius AG
Thermo Fisher Scientific Inc.
BBI Solutions
FUJIFILM Irvine Scientific Inc.
Gemini Bioproducts LLC
HiMedia Laboratories
InVitria, Kingfisher Biotech
Novus Biologicals LLC
R&D Systems
Sino Biological Inc.
STEMCELL Technologies Inc

Market Segmentation:

The recombinant cell culture supplements Market is segmented on the basis of product, application, and expression system. Product segment includes recombinant albumin (rAlbumin), recombinant insulin (rInsulin), recombinant epidermal growth factor (rEGF), recombinant interleukin growth factor (rILGF), recombinant transferrin (rTransferrin), recombinant trypsin (rTrypsin), recombinant Insulin-like growth factor (rIGF), recombinant stem cell factor (rSCF), recombinant aprotinin (rAprotinin), recombinant lysozyme (rLysozyme), and others. Application segment includes stem cell and regenerative medicine, Bio-Production, and academic and research application. The expression system segment includes Mammalian, E. Coli, Yeast, and others.

Based On Application, The Stem Cell And Regenerative Medicine Segment Is Accounted As A Major Contributor In The Recombinant Cell Culture Supplements.

Stem cell and regenerative medicine held a commanding market share in 2022, leading the global market for recombinant cell culture supplements (by application). But due to improved cell viability and batch-to-batch uniformity of final products, academic and research applications are identified to be the fastest expanding segment over the forecast period.

Mammalian Expression System Segment Witnessed Growth At A Rapid Rate

With a significant market share in 2022, the mammalian expression system dominated the recombinant cell culture supplements market. Stable cell lines produced from mammalian cells are used by the majority of biopharmaceutical businesses in the world to produce biologics.

North America Dominated The Market For Additives To Recombinant Cell Culture In The Region

In 2022, North America dominated the market for supplements used in recombinant cell cultures. The expansion can be linked to the region's inclusion of essential players as well as the accessibility of money and technology for recombinant cell culture supplements.